Wellington Management Group
LXEO icon

Wellington Management Group’s Lexeo Therapeutics LXEO Stock Holding History

Wellington Management Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$942K Buy
202,383
+29,680
+17% +$161K ﹤0.01% 1757
2026
Q1 		$991K Buy
172,703
+89,473
+108% +$634K ﹤0.01% 1678
2025
Q4 		$826K Buy
+83,230
New +$759K ﹤0.01% 1750
2025
Q1 		– Sell
-76,981
Closed -$507K – 2003
2024
Q4 		$507K Buy
76,981
+25,089
+48% +$198K ﹤0.01% 1829
2024
Q3 		$469K Buy
51,892
+29,791
+135% +$355K ﹤0.01% 1826
2024
Q2 		$355K Buy
+22,101
New +$321K ﹤0.01% 1814

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Wellington Management Group's LXEO Position: Q2 2026 in Review

Wellington Management Group increased its Lexeo Therapeutics (LXEO) stake by 17% in Q2 2026, buying an estimated $161K and bringing the position to 202,383 shares worth $942K. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

Wellington Management Group first reported a position in LXEO in Q2 2024 and has held it in 6 quarters since. The position peaked at $991K in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Wellington Management Group held 202,383 shares of Lexeo Therapeutics worth $942K as of Q2 2026.
  • Wellington Management Group bought 29,680 Lexeo Therapeutics shares in Q2 2026, an estimated $161K.
  • Lexeo Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1757 holding.
  • Wellington Management Group first reported a position in Lexeo Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Wellington Management Group's Lexeo Therapeutics position peaked at $991K in Q1 2026.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.